[BUY] Rio Tinto (ASX: RIO) – Oyu Tolgoi and Simandou Carry the Growth Case After an In-Line Quarter
ASX: RIO▼ -0.59%
Buy, A$176.30 sell-side target, 20.5 per cent upside. Oyu Tolgoi lifts Rio Tinto’s 3Q26 copper as Simandou ramps and guidance holds.
ASX Research
[BUY] Sonic Healthcare (ASX: SHL) – Medicare Lab Fee Cuts Land Close to Company Estimates
ASX: SHL▲ +1.06%
Buy, A$23.70 target, 24.9 per cent upside per institutional sell-side research. Sonic Healthcare’s US lab fee cuts land near company estimates.
[BUY] Bellevue Gold (ASX: BGL) – Contractor Hiccup Masks a Looming Cash Flow Inflection
ASX: BGL▲ +0.35%
Buy, A$1.90 target and 32.9 per cent upside per institutional sell-side research, as Bellevue Gold’s hedge book clears in FY27.
[BUY] Chrysos (ASX: C79) – Pipeline Depth Answers the FY27 Deployment Question
ASX: C79▲ +1.39%
Buy rated by institutional sell-side research, A$10.26 target, about 50.9 per cent upside. Chrysos has a 24-unit high-confidence pipeline for FY27.
[BUY] Worley (ASX: WOR) – Growth Without the Lump Sum Risk
ASX: WOR▲ +0.10%
Buy-rated Worley kept 77 per cent of FY26 revenue reimbursable while pushing into full project delivery. Target A$13.00, 31.8% upside, 5.1% yield.
[HOLD] Sims (ASX: SGM) – US Scrap Strength Meets a Data Centre Recycling Pause
ASX: SGM▼ -1.55%
Hold, A$24.80 sell-side target for Sims (ASX: SGM), 1.9 per cent above A$24.33, as a strong US scrap result meets softer data centre recycling.
[BUY] Qantas (ASX: QAN) – The Fleet Renewal Is the Margin Story
ASX: QAN▼ -0.23%
Buy-rated Qantas targets a 10-12% international margin from FY32 against 3.7% in FY26. Target A$12.45, 32.6% upside, 4.2% fully franked yield.
[BUY] Amcor (ASX: AMC) – A 5.6% Yield as Volumes Turn
ASX: AMC▲ +0.03%
Amcor is a Buy with a A$81.40 target, 24.4% upside from A$65.44. June quarter volumes turned positive, EBIT rose 22%, and the unfranked yield is about 5.6%.
[BUY] Life360 (ASX: 360) – The Market Sold a 38% Revenue Quarter
ASX: 360▲ +0.87%
Life360 grew revenue 38% and adjusted EBITDA 53% in the June quarter, yet the CDIs fell 19% on the day. We rate it a Buy with a A$30.95 target.
[BUY] Breville Group (ASX: BRG) – The Coffee Fear Is Priced In, The Margin Recovery Is Not
ASX: BRG▲ +0.56%
Breville Group (ASX: BRG) at A$31.05, on about 29x FY27 earnings and near its own ten-year average while peers re-rate. Buy, about 22% upside.